DK164893C - Kombinationspraeparat paa enhedsdosisform indeholdende et xanthinderivat og o-acetylsalicylsyre eller dens farmakolgisk acceptable salte samt fremgangsmaade til dets fremstilling - Google Patents

Kombinationspraeparat paa enhedsdosisform indeholdende et xanthinderivat og o-acetylsalicylsyre eller dens farmakolgisk acceptable salte samt fremgangsmaade til dets fremstilling

Info

Publication number
DK164893C
DK164893C DK330685A DK330685A DK164893C DK 164893 C DK164893 C DK 164893C DK 330685 A DK330685 A DK 330685A DK 330685 A DK330685 A DK 330685A DK 164893 C DK164893 C DK 164893C
Authority
DK
Denmark
Prior art keywords
carbon atoms
formula
preparation
procedures
dosage form
Prior art date
Application number
DK330685A
Other languages
Danish (da)
English (en)
Other versions
DK164893B (da
DK330685D0 (da
DK330685A (da
Inventor
Klaus Ulrich Weithmann
Dirk Seiffge
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25823161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK164893(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of DK330685D0 publication Critical patent/DK330685D0/da
Publication of DK330685A publication Critical patent/DK330685A/da
Publication of DK164893B publication Critical patent/DK164893B/da
Application granted granted Critical
Publication of DK164893C publication Critical patent/DK164893C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK330685A 1984-07-21 1985-07-19 Kombinationspraeparat paa enhedsdosisform indeholdende et xanthinderivat og o-acetylsalicylsyre eller dens farmakolgisk acceptable salte samt fremgangsmaade til dets fremstilling DK164893C (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3426961 1984-07-21
DE3426961 1984-07-21
DE19853508097 DE3508097A1 (de) 1984-07-21 1985-03-07 Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung
DE3508097 1985-03-07

Publications (4)

Publication Number Publication Date
DK330685D0 DK330685D0 (da) 1985-07-19
DK330685A DK330685A (da) 1986-01-22
DK164893B DK164893B (da) 1992-09-07
DK164893C true DK164893C (da) 1993-01-25

Family

ID=25823161

Family Applications (1)

Application Number Title Priority Date Filing Date
DK330685A DK164893C (da) 1984-07-21 1985-07-19 Kombinationspraeparat paa enhedsdosisform indeholdende et xanthinderivat og o-acetylsalicylsyre eller dens farmakolgisk acceptable salte samt fremgangsmaade til dets fremstilling

Country Status (16)

Country Link
US (2) US4880791A (ja)
EP (2) EP0169466B1 (ja)
JP (1) JPH0749374B2 (ja)
AT (2) ATE84967T1 (ja)
AU (1) AU573866B2 (ja)
CA (1) CA1247530A (ja)
DE (3) DE3508097A1 (ja)
DK (1) DK164893C (ja)
HK (1) HK81792A (ja)
HU (1) HU199291B (ja)
IE (1) IE58611B1 (ja)
IL (1) IL75851A (ja)
NZ (1) NZ212796A (ja)
PH (1) PH22730A (ja)
PT (1) PT80828B (ja)
SG (1) SG79592G (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3576119D1 (de) * 1984-07-21 1990-04-05 Hoechst Ag Kombinationspraeparat aus pyrimido-pyrimidinen und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung.
DE3508097A1 (de) * 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung
DE3524051A1 (de) * 1985-07-05 1987-01-15 Hoechst Ag Kombinationspraeparate aus hemmstoffen der thrombozytenaggregation und deren verwendung
DE3623331A1 (de) * 1986-07-11 1988-01-21 Hoechst Ag Konfektionspackungen, enthaltend arzneimittelkombinationen fuer zeitlich abgestufte anwendung
US5196430A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5196429A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
DE3707532C2 (de) * 1987-03-09 1998-05-28 Bauer Johann Verwendung einer Kombination von Extr. Gingko biloba oder mindestens einem Gingkolid und Acetylsalicylsäure oder DL-Lysin-mono-acetylsalicylat oder Diflunisal zur Behandlung von Verbrennungen, Verbrühungen, Strahlenschäden und Erfrierungen
DE3717337A1 (de) * 1987-05-22 1988-12-15 Hoechst Ag Verfahren zum nachweis der antiaggregatorischen wirkung von vasoaktiven stoffen, speziell von phosphodiesterase- und/oder cyclooxygenase-hemmern
JPH0182099U (ja) * 1987-11-25 1989-06-01
US5077296A (en) * 1987-12-03 1991-12-31 Hyal Pharmaceutical Corporation Method for treating equine navicular disease with pentoxifylline, and composition containing pentoxifylline for administrating to horses
JP2661666B2 (ja) * 1988-02-19 1997-10-08 ヘキスト薬品工業株式会社 抗消化性潰瘍剤
US5055460A (en) * 1990-04-26 1991-10-08 Mitchell Friedlander Method for weight loss
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
US5795897A (en) * 1992-11-18 1998-08-18 Cell Therapeutics, Inc. Oxohexyl methylxanthine compounds
WO1995019171A1 (en) * 1994-01-14 1995-07-20 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
DE19732323C2 (de) * 1996-08-06 1999-08-19 Dunzendorfer Medikamentenkombination zur erhöhten Wirkstoffkonzentration in Geweben
US6592901B2 (en) * 2001-10-15 2003-07-15 Hercules Incorporated Highly compressible ethylcellulose for tableting
US6866876B2 (en) * 2002-02-14 2005-03-15 Wm. Wrighley Jr. Company Coated chewing gum products containing hydrogenated indigestible starch syrup as a binding agent
US20040209900A1 (en) * 2003-04-15 2004-10-21 Hauptman Stephen P. Treatment of lipodystrophy (lipid redistribution syndrome)
MX2007001563A (es) * 2004-08-04 2008-03-05 Johnson & Johnson Composicion para liberacion sostenida de farmaco que demuestra un patron de liberacion ascendente del orden cero, metodos para la elaboracion de dicha composicion.
CA2716788C (en) 2008-02-29 2016-08-16 Concert Pharmaceuticals, Inc. Deuterium-substituted xanthine derivatives
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
EP2473052A4 (en) 2009-09-02 2013-03-20 Concert Pharmaceuticals Inc SUBSTITUTED XANTHINE DERIVATIVES
WO2012031138A2 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3-7-dimethyl-1h-purine-2,6(3h,7h)dione
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013155465A1 (en) 2012-04-13 2013-10-17 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013159006A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Polymorphs of (s)-1-(4,4,6,6,6-pentadeutero-5-hydroxyhexyl)-3,7-dimethyl-1h-purine-2,6(3h,7h)-dione
KR101512223B1 (ko) * 2013-02-22 2015-04-24 가톨릭대학교 산학협력단 펜톡시필린을 포함하는 항암치료 보조제
CN117919188B (zh) * 2024-01-19 2024-08-13 山东京卫制药有限公司 一种己酮可可碱缓释片剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2646385A (en) * 1951-06-01 1953-07-21 Mozes J Lewenstein Pharmaceutical product for dysmenorrhea
US3080287A (en) * 1957-08-05 1963-03-05 Lewenstein Mozes Juda Analgesic compositions
DE1492081A1 (de) * 1961-03-04 1969-04-03 Pfizer Gmbh Verfahren zur Herstellung von leicht einnehmbaren Presstabletten
US3218233A (en) * 1963-01-24 1965-11-16 Lewenstein Mozes Juda Analgesic compositions
US3350270A (en) * 1964-09-18 1967-10-31 Leeds Dixon Lab Inc Aluminum aspirin film-enveloped therapeutic agents in sustained release dosage form
US3488418A (en) * 1965-11-18 1970-01-06 Sterling Drug Inc Sustained relief analgesic composition
FR7217M (ja) * 1967-02-01 1969-08-25
US3829569A (en) * 1967-10-27 1974-08-13 Tri Kem Corp Therapeutic composition and method for its use
US3864469A (en) * 1967-12-16 1975-02-04 Hoechst Ag Xanthines in pharmaceutical preparations and for stabilization of vitamins
GB1357737A (en) * 1970-10-09 1974-06-26 Arpic Sa Sustained release pharmaceutical compositions
US3906086A (en) * 1971-07-19 1975-09-16 Richard G Powers Timed-release aspirin
US4025613A (en) * 1971-07-19 1977-05-24 Richard G. Powers Timed-release aspirin
US3946110A (en) * 1974-05-30 1976-03-23 Peter, Strong Research And Development Company, Inc. Medicinal compositions and methods of preparing the same
DE2520978C3 (de) * 1975-05-10 1981-02-19 Hoechst Ag, 6000 Frankfurt Dosierungseinheit einer festen, oral zu verabreichenden Arzneiform von wasserlöslichen Xanthin-Derivaten
DE2831728C2 (de) * 1978-07-19 1982-12-23 Krewel-Werke Gmbh, 5208 Eitorf Arzneimittel zur Behandlung von Kopfschmerzen
US4361545A (en) * 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
US4547358A (en) * 1980-05-06 1985-10-15 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
ES501162A0 (es) * 1981-04-07 1982-02-01 Coma Julia Concepcion Procedimiento para la obtencion de acetilsalicilato de 7-(2-dietilaminoetil)-teofilina
DE3127237A1 (de) * 1981-07-10 1983-01-20 Hoechst Ag, 6000 Frankfurt Magenvertraegliche arzneiformen von xanthinderivaten und verfahren zu ihrer herstellung
US4375468A (en) * 1981-07-13 1983-03-01 Verex Laboratories, Inc. Constant order release aspirin composition and method of treating arthritis
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4520009A (en) * 1983-11-28 1985-05-28 Verex Laboratories, Inc. Sustained released aspirin formulation
DE3346571A1 (de) * 1983-12-23 1985-07-04 Bayer Ag, 5090 Leverkusen Oral retardierte acetylsalicylsaeureformulierungen
DE3508097A1 (de) * 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung
DE3576119D1 (de) * 1984-07-21 1990-04-05 Hoechst Ag Kombinationspraeparat aus pyrimido-pyrimidinen und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung.
DE3529497A1 (de) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel

Also Published As

Publication number Publication date
IE851820L (en) 1986-01-21
IL75851A (en) 1991-01-31
DE3576912D1 (de) 1990-05-10
US4975432A (en) 1990-12-04
NZ212796A (en) 1988-07-28
DK164893B (da) 1992-09-07
DK330685D0 (da) 1985-07-19
HUT38256A (en) 1986-05-28
DE3508097A1 (de) 1986-02-06
DE3587050D1 (de) 1993-03-11
SG79592G (en) 1992-10-02
EP0169466B1 (de) 1990-04-04
JPH0749374B2 (ja) 1995-05-31
EP0351885A1 (de) 1990-01-24
US4880791A (en) 1989-11-14
PH22730A (en) 1988-11-28
EP0169466A3 (en) 1986-05-21
PT80828A (de) 1985-08-01
AU4519385A (en) 1986-01-23
AU573866B2 (en) 1988-06-23
CA1247530A (en) 1988-12-28
HK81792A (en) 1992-10-30
HU199291B (en) 1990-02-28
EP0351885B1 (de) 1993-01-27
IL75851A0 (en) 1985-11-29
DK330685A (da) 1986-01-22
IE58611B1 (en) 1993-10-20
EP0169466A2 (de) 1986-01-29
ATE51521T1 (de) 1990-04-15
ATE84967T1 (de) 1993-02-15
PT80828B (pt) 1987-10-20
JPH05246851A (ja) 1993-09-24

Similar Documents

Publication Publication Date Title
DK164893C (da) Kombinationspraeparat paa enhedsdosisform indeholdende et xanthinderivat og o-acetylsalicylsyre eller dens farmakolgisk acceptable salte samt fremgangsmaade til dets fremstilling
LU90192I2 (fr) Desirudine et ses sels et dérivés pharmaceutiquement acceptables (revasc)
SE8402551L (sv) Cinnamoylmoranolin-derivat
NL990001I1 (nl) Geneesmiddel, dat dipyridamol of modipamol en O-acetylsalicylzuur resp. fysiologisch verdraagbare zouten daarvan, bevat, werkwijze voor de bereiding daarvan en toepassing daarvan voor het bestrijden van thrombusvorming.
IT8248200A0 (it) Preparato farmaceutico per la cura del diabete mellitus
ES2062610T3 (es) Compuesto diarilico anti-ateroesclerotico.
FI861655A0 (fi) Menetelmä lääkeaineina käyttökelpoisten griseoliinihapon johdannaisten valmistamiseksi
ZA828639B (en) Novel triazoloquinazolinones, their preparation and pharmaceutical formulations containing these compounds
IT8219482A0 (it) Composizione farmaceutica per la cura di affezioni della cavita'orale.
DK429480A (da) Phosphonohydroxyeddikesyre fremgangsmaader til fremstilling deraf samt anvendelse deraf som laegemiddel
ES538982A0 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.
ES2052670T3 (es) Utilizacion de derivados de 2-pirimidinil-1-piperazina.
FI884911A (fi) Laekemedel, i dessa saosom aktiva aemnen befintliga fosforin innehaollande 2-isoxazoliner och isoxazoler samt foerfarande foer framstaellning av dessa heterocykliska foereningar.
NO851145L (no) N-bicykloheptyl- og n-bicykloheptenyl-imidazoler, fremgangsmaate til deres fremstilling, deres anvendelse samt farmasoeytiske preparater
SE8107833L (sv) Substituerade tetrahydro-1,2,4-oxadiazin-5-on-derivat med kramplosande verkan, sett for deras framstellning och farmaceutiska beredningar innehallandedem
EP0208962A3 (en) Combination preparations from thrombocyte aggregation inhibitors, and their use

Legal Events

Date Code Title Description
PBP Patent lapsed